keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonate

keyword
https://www.readbyqxmd.com/read/28938420/bone-structural-characteristics-and-response-to-bisphosphonate-treatment-in-children-with-hajdu-cheney-syndrome
#1
Sophia Sakka, Rachel I Gafni, Justin H Davies, Bart Clarke, Peter Tebben, Mark Samuels, Vrinda Saraff, Klaus Klaushofer, Nadja Fratzl-Zelman, Paul Roschger, Frank Rauch, Wolfgang Högler
Context: Hajdu-Cheney syndrome (HJCYS) is a rare, multisystem, bone disease caused by heterozygous mutations in the NOTCH2 gene. Histomorphometric and bone ultrastructural analyses in children have not been reported and sparse evidence exists on response to bisphosphonate (BP) therapy. Objective: To investigate clinical and bone histomorphometric characteristics, bone matrix mineralization and the response of bone geometry and density to BP therapy. Patients: Five children with HJCYS (3 males) aged between 6...
September 8, 2017: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28937990/treatment-of-opg-deficient-mice-with-wp9qy-a-rankl-binding-peptide-recovers-alveolar-bone-loss-by-suppressing-osteoclastogenesis-and-enhancing-osteoblastogenesis
#2
Yuki Ozaki, Masanori Koide, Yuriko Furuya, Tadashi Ninomiya, Hisataka Yasuda, Midori Nakamura, Yasuhiro Kobayashi, Naoyuki Takahashi, Nobuo Yoshinari, Nobuyuki Udagawa
Osteoblasts express two key molecules for osteoclast differentiation, receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), a soluble decoy receptor for RANKL. RANKL induces osteoclastogenesis, while OPG inhibits it by blocking the binding of RANKL to RANK, a cellular receptor of RANKL. OPG-deficient (OPG-/-) mice exhibit severe alveolar bone loss with enhanced bone resorption. WP9QY (W9) peptide binds to RANKL and blocks RANKL-induced osteoclastogenesis. W9 is also reported to stimulate bone formation in vivo...
2017: PloS One
https://www.readbyqxmd.com/read/28937683/a-vitronectin-derived-peptide-reverses-ovariectomy-induced-bone-loss-via-regulation-of-osteoblast-and-osteoclast-differentiation
#3
Seung-Ki Min, Hyun Ki Kang, Sung Youn Jung, Da Hyun Jang, Byung-Moo Min
Osteoporosis affects millions of people worldwide by promoting bone resorption and impairing bone formation. Bisphosphonates, commonly used agents to treat osteoporosis, cannot reverse the substantial bone loss that has already occurred by the time of diagnosis. Moreover, their undesirable side-effects, including osteonecrosis of the jaw, have been reported. Here, we demonstrated that a new bioactive core vitronectin-derived peptide (VnP-16) promoted bone formation by accelerating osteoblast differentiation and activity through direct interaction with β1 integrin followed by FAK activation...
September 22, 2017: Cell Death and Differentiation
https://www.readbyqxmd.com/read/28936606/denosumab-significantly-improves-bone-mineral-density-with-or-without-bisphosphonate-pre-treatment-in-osteoporosis-with-rheumatoid-arthritis-denosumab-improves-bone-mineral-density-in-osteoporosis-with-rheumatoid-arthritis
#4
Yukio Nakamura, Takako Suzuki, Hiroyuki Kato
Bone mineral density (BMD) sometimes cannot be improved by long-term bisphosphonate (BP) therapy in osteoporosis (OP) patients with rheumatoid arthritis (RA). This study showed that BMD significantly increased after denosumab treatment in patients with long-term BP pre-treatment as much as in treatment-naïve patients. Thus, denosumab can be a strong OP treatment option for long-term BP pre-treated RA patients. INTRODUCTION: The aim of this 24-month retrospective study was to evaluate differences in outcomes of denosumab with or without bisphosphonate (BP) pre-treatment in osteoporosis (OP) patients with rheumatoid arthritis (RA)...
September 21, 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28936581/exploring-methods-for-comparing-the-real-world-effectiveness-of-treatments-for-osteoporosis-adjusted-direct-comparisons-versus-using-patients-as-their-own-control
#5
Linda Karlsson, Johan Mesterton, Maurille Feudjo Tepie, Michele Intorcia, Jetty Overbeek, Oskar Ström
Using Swedish and Dutch registry data for women initiating bisphosphonates, we evaluated two methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for differences in patient baseline characteristics. Each method has advantages and disadvantages; both are potential complements to clinical trial analyses. PURPOSE: We evaluated methods of comparing the real-world effectiveness of osteoporosis treatments that attempt to adjust for both observed and unobserved confounding...
September 21, 2017: Archives of Osteoporosis
https://www.readbyqxmd.com/read/28936298/the-role-of-leucocyte-rich-and-platelet-rich-fibrin-l-prf-in-the-treatment-of-the-medication-related-osteonecrosis-of-the-jaws-mronj
#6
REVIEW
Jorge A Cano-Durán, Juan-Francisco Peña-Cardelles, Daniel Ortega-Concepción, Víctor M Paredes-Rodríguez, Mariano García-Riart, Juan López-Quiles
BACKGROUND: For the treatment of the bisphosphonates and other drugs related osteonecrosis of the jaws, currently medication-related osteonecrosis of the jaws (MRONJ), have been established different conservative therapeutic approaches, avoiding surgery except in cases of extreme need. Given the controversy and lack of current consensus regarding MRONJ therapy in patients, new techniques have been developed among which the use of fibrin membranes rich in platelets and leukocytes (L-PRF)...
August 2017: Journal of Clinical and Experimental Dentistry
https://www.readbyqxmd.com/read/28935593/factors-affecting-peri-implant-fracture-following-locking-plate-for-osteoporotic-distal-femur-fractures
#7
Ki-Chul Park, Seung-Jae Lim, Young Sik Song, Kyu-Tae Hwang
INTRODUCTION: The purpose of this study is to evaluate the outcomes and to analyze the risk factors for the occurrence of peri-implant fracture after treatment of osteoporotic distal femoral fracturesusing a locking plate. HYPOTHESIS: Risk factors affecting peri-implant fracture exist after locking plate fixation in osteoporotic distal femur fracture. MATERIALS AND METHODS: Eighty nine(88 patients) with osteoporotic distal femoral fractures were evaluated between January2006 and January2014...
September 18, 2017: Orthopaedics & Traumatology, Surgery & Research: OTSR
https://www.readbyqxmd.com/read/28934971/assessment-classification-and-treatment-of-calcinosis-as-a-complication-of-juvenile-dermatomyositis-a-survey-of-pediatric-rheumatologists-by-the-childhood-arthritis-and-rheumatology-research-alliance-carra
#8
A B Orandi, K W Baszis, V R Dharnidharka, A M Huber, M F Hoeltzel
BACKGROUND: There is no standardized approach to the management of JDM-associated calcinosis and its phenotypes. Current knowledge of treatment outcomes is confined to small series and case reports. We describe physician perspectives toward diagnostic approach, classification and treatment directly targeting calcinosis, independent of overall JDM therapy. METHODS: An electronic survey of 22 questions was organized into sections regarding individual practices of assessment, classification and treatment of calcinosis, including perceived successes of therapies...
September 21, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/28931828/a-novel-h2s-releasing-amino-bisphosphonate-which-combines-bone-anti-catabolic-and-anabolic-functions
#9
Simona Rapposelli, Laura Gambari, Maria Digiacomo, Valentina Citi, Gina Lisignoli, Cristina Manferdini, Vincenzo Calderone, Francesco Grassi
Bisphosphonates (BPs) are the first-line treatment of bone loss resulting from various pathological conditions. Due to their high affinity to bone they have been used to develop conjugates with pro-anabolic or anti-catabolic drugs. We recently demontrated that hydrogen sulfide (H2S), promotes osteogenesis and inhibits osteoclast differentiation. Here we developed an innovative molecule, named DM-22, obtained from the combination of alendronate (AL) and the H2S-releasing moiety aryl-isothiocyanate. DM-22 and AL were assayed in vitro in the concentration range 1-33 μM for effects on viability and function of human osteoclasts (h-OCs) and mesenchymal stromal cells (h-MSCs) undergoing osteogenic differentiation...
September 20, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28928654/adenosine-receptor-stimulation-improves-glucocorticoid-induced-osteoporosis-in-a-rat-model
#10
Gabriele Pizzino, Natasha Irrera, Federica Galfo, Giacomo Oteri, Marco Atteritano, Giovanni Pallio, Federica Mannino, Angelica D'Amore, Enrica Pellegrino, Federica Aliquò, Giuseppe P Anastasi, Giuseppina Cutroneo, Francesco Squadrito, Domenica Altavilla, Alessandra Bitto
Glucocorticoid-induced osteoporosis (GIO) is a secondary cause of bone loss. Bisphosphonates approved for GIO, might induce jaw osteonecrosis; thus additional therapeutics are required. Adenosine receptor agonists are positive regulators of bone remodeling, thus the efficacy of adenosine receptor stimulation for treating GIO was tested. In a preventive study GIO was induced in Sprague-Dawley rats by methylprednisolone (MP) for 60 days. Animals were randomly assigned to receive polydeoxyribonucleotide (PDRN), an adenosine A2 receptor agonist, or PDRN and DMPX (3,7-dimethyl-1-propargylxanthine, an A2 antagonist), or vehicle (0...
2017: Frontiers in Pharmacology
https://www.readbyqxmd.com/read/28921820/systematic-review-and-network-meta-analysis-on-the-relative-efficacy-of-osteoporotic-medications-men-with-prostate-cancer-on-continuous-androgen-deprivation-therapy%C3%A2-to-reduce-risk-of-fragility-fractures
#11
REVIEW
Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan, Murray Krahn
BACKGROUND: Androgen deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This analysis evaluated the relative effectiveness of osteoporosis treatments using BMD as a surrogate endpoint for fragility fractures in men on continuous ADT. METHOD: We included randomized controlled trials studying bisphosphonates, denosumab, toremifene, and raloxifene in patients with non-metastatic prostate cancer on ADT for review...
September 18, 2017: BJU International
https://www.readbyqxmd.com/read/28921338/the-effect-of-high-dose-vitamin-d3-supplementation-on-bone-mineral-density-in-subjects-with-prediabetes
#12
A U Larsen, G Grimnes, R Jorde
The rationale of this study was to determine the effect of high-dose vitamin D3 supplementation on bone mineral density (BMD). Prediabetic males given vitamin D had significantly less reduction in BMD at the femoral neck compared to the controls. The clinical implications of our findings require further investigation. INTRODUCTION: Type 2 diabetes mellitus is associated with increased fracture risk, and recent studies show crosstalk between bone and glucose metabolism. Few studies have investigated the effect of vitamin D supplementation on the bone without additional calcium...
September 18, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28917085/a-retrospective-review-of-initial-bisphosphonate-infusion-in-an-inpatient-vs-outpatient-setting-for-bisphosphonate-na%C3%A3-ve-patients
#13
Rose M Kreikemeier, Heather Gosnell, Lisa M Halbur, Eric T Rush
BACKGROUND: The purpose of this study was to evaluate the safety and convenience of initial bisphosphonate infusion therapy in inpatient and outpatient settings for patients with low bone mineral density. METHODS: All data were collected from retrospective chart reviews of heterogeneous groups of patients. Abnormal findings prior to the infusion and side effects during the infusion were documented. Patients were contacted following the infusion to discuss post-infusion adverse events...
September 16, 2017: Journal of Pediatric Endocrinology & Metabolism: JPEM
https://www.readbyqxmd.com/read/28916324/in%C3%A2-vitro-investigation-of-the-antimicrobial-effect-of-three-bisphosphonates-against-different-bacterial-strains
#14
Michael A Ermer, Simon C Kottmann, Jörg-Elard Otten, Annette Wittmer, Philipp Poxleitner, Klaus Pelz
PURPOSE: Since the first descriptions of medication-related osteonecrosis of the jaw (MRONJ) in 2003, the pathogenesis has remained unanswered. Recent histomorphometric studies have found several microorganisms, including Actinomyces, Bacillus, Fusobacterium, Staphylococcus, Streptococcus, Selenomonas, Treponema, and Candida albicans in necrotic bone. Polymerase chain reaction studies have recently confirmed the occurrence of 48 genera. Only a few studies have examined the antimicrobial effect of bisphosphonates (BPs)...
August 31, 2017: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28915955/implications-of-bisphosphonate-calcium-ion-depletion-interfering-with-desmosome-epithelial-seal-in-osseointegrated-implants-and-pressure-ulcers
#15
Louis Z G Touyz, Kelvin I Afrashtehfar
Osteoporosis (OP) is a global bone disease prevalent in aging in humans, especially in older women. Bisphosphonates (BPs) are commonly used as therapy for OP as it influences hard and soft tissues calcium metabolism. Mucosal and dermal ulceration with exposure of underlying bone arises from incomplete epithelial recovery due to reduced desmosome formation deriving from lack of available calcium. Pathological situations such as bisphosphonate-related osteonecrosis of the jaw have been described. This hypothesis states other situations which demand intact functional desmosomes such as healing skin over chronic pressure points leading to pressure ulcers (as well-known as bedsores, pressure sores, pressure injuries, decubitus ulcers), and hemidesmosomes such as epithelial seals in contact with titanium surfaces will have a higher prevalence of breakdown among patients being treated with BPs...
September 2017: Medical Hypotheses
https://www.readbyqxmd.com/read/28914765/statin-and-bisphosphonate-induce-starvation-in-fast-growing-cancer-cell-lines
#16
Heidrun Karlic, Florian Haider, Roman Thaler, Silvia Spitzer, Klaus Klaushofer, Franz Varga
Statins and bisphosphonates are increasingly recognized as anti-cancer drugs, especially because of their cholesterol-lowering properties. However, these drugs act differently on various types of cancers. Thus, the aim of this study was to compare the effects of statins and bisphosphonates on the metabolism (NADP⁺/NADPH-relation) of highly proliferative tumor cell lines from different origins (PC-3 prostate carcinoma, MDA-MB-231 breast cancer, U-2 OS osteosarcoma) versus cells with a slower proliferation rate like MG-63 osteosarcoma cells...
September 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28913325/bone-loss-prevention-of-bisphosphonates-in-patients-with-inflammatory-bowel-disease-a-systematic-review-and-meta-analysis
#17
REVIEW
Yan Hu, Xiaoting Chen, Xiaojing Chen, Shuang Zhang, Tianyan Jiang, Jing Chang, Yanhong Gao
OBJECTIVE: The purpose of this study was to evaluate the effect of bisphosphonates in improving bone mineral density (BMD) and decreasing the occurrence rate of fractures and adverse events in patients with inflammatory bowel disease (IBD). METHODS: Randomized controlled trials (RCTs) which use bisphosphonates in IBD patients were identified in PubMed, MEDLINE database, EMBASE database, Web of Knowledge, and the Cochrane Databases between 1990 and June 2016. People received bisphosphonate or placebos with a follow-up of at least one year were also considered...
2017: Canadian Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28905737/giant-cell-tumor-of-bone-revisited
#18
Andreas F Mavrogenis, Vasileios G Igoumenou, Panayiotis D Megaloikonomos, Georgios N Panagopoulos, Panayiotis J Papagelopoulos, Panayotis N Soucacos
Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4-10% of all bone tumors and typically affects the meta-epiphyseal region of long bones of young adults. The most common site involved is the distal femur, followed by the distal radius, sacrum, and proximal humerus. Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint...
2017: SICOT-J
https://www.readbyqxmd.com/read/28902603/the-utility-of-conservative-treatment-modalities-in-the-management-of-osteonecrosis
#19
Feroz Osmani, Savyasachi Thakkar, Jonathan Vigdorchik
INTRODUCTION: Osteonecrosis is an ischemic pathologic process associated with a number of conditions affecting a range of age groups. The problem faced in the management of osteonecrosis is whether conservative treatment is a viable and effective option for patients. In this systematic review, we investigated the efficacy of various nonoperative treatment modalities for hip and knee osteonecrosis, including pharmacological management and biophysical modalities. METHODS: We identified 16 studies based on electronic searches through the PubMed, Embase, CINAHL Plus, and Cochrane databases from January 2001 to November 2015...
May 2017: Bulletin of the Hospital for Joint Diseases
https://www.readbyqxmd.com/read/28902456/safety-and-efficacy-of-hydroxyapatite-scaffold-in-the-prevention-of-jaw-osteonecrosis-in-vivo
#20
Adriana Duarte de Almeida, Fernanda Gomes Leite, Marco Vinícius Chaud, Márcia de Araújo Rebelo, Liliane Cristine Ferreira de Souza Borges, Fabia Judice Marques Viroel, Alessandre Hataka, Denise Grotto
Two scaffolds of chitosan/sodium alginate/hydroxyapatite (Ch/NaAlg/Hap) 1:1:0.2 and 1:1:0.6 were evaluated in the prevention of bisphosphonate-induced jaw osteonecrosis. Two groups of rats (n = 24, according to the euthanasia time: 15 or 30 days after the last Zoledronic acid (ZA) administration) were subdivided in four subgroups (n = 6): I - Control (saline + teeth extraction); II - ZA 0.6 mg/kg + teeth extraction; III - ZA + teeth extraction + scaffold 1:1:0.2; IV - ZA + teeth extraction + scaffold 1:1:0...
September 13, 2017: Journal of Biomedical Materials Research. Part B, Applied Biomaterials
keyword
keyword
49305
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"